Stocks Health care SLN
NASDAQ · Health careSilence Therapeutics plc (SLN)
Silence Therapeutics plc brought in $615K of revenue over the twelve months to June 30, 2026, down 97.7% from a year earlier. It posted a net loss of $60M. In fiscal 2025 capital spending exceeded operating cash flow by $62.3M. At June 30, 2026 it held $72.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Watch SLN in 60 secondsWhat Silence Therapeutics plc does
Silence Therapeutics plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SLN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $559K | -$88.6M | -$0.63 | -$62.3M |
| 2024 | $43.3M | -$45.3M | -$0.33 | -$67.9M |
| 2024 | $31.6M | -$54.2M | -$0.49 | -$49.5M |
| 2022 | $21.7M | -$50.3M | -$0.52 | -$57.2M |
Full financial statements: income, balance sheet and cash flow
Where SLN ranks in Health care
Latest SEC filings
What Silence Therapeutics plc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Activist stake changed SCHEDULE 13D/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 12, 2026
- August 11, 2026Form S-3MEF filing S-3MEF
- August 10, 2026
- August 10, 2026
- August 10, 2026
- August 10, 2026
- July 16, 2026
Insider trades
What the people running Silence Therapeutics plc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns SLN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Richard Ian Griffiths13D, may seek influence with 1 related filers | 16.9% | March 27, 2024 |
| Richard Griffiths13D, may seek influence | 7.97% | August 13, 2026 |
| Raymond Debbane13G, passive with 7 related filers | 7% | August 13, 2026 |
Largest institutional holders
Insiders
Questions about SLN
What does Silence Therapeutics plc do?
Silence Therapeutics plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SLN.
Is Silence Therapeutics plc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $60M on revenue of $615K.
How much revenue does Silence Therapeutics plc make?
Over the twelve months to June 30, 2026 Silence Therapeutics plc reported revenue of $615K. That is 97.7% less than a year earlier.
When did Silence Therapeutics plc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the activist stake changed from August 13, 2026.
Similar companies
Compare SLN with
Follow SLN
Get an email when Silence Therapeutics plc files with the SEC: results, executive changes, material agreements and annual reports.
Follow SLN: get an email when it filesWhere the numbers come from
Financial figures are the values Silence Therapeutics plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.